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ABSTRACT
Background Patients with non-resectable glioblastoma
generally exhibit a poor prognosis, even after
radiotherapy plus concomitant and adjuvant
temozolomide (XRT/TMZ/TMZ). Unfortunately, no
data are available concerning the predictive value of
O6-methylguanine-DNA methyltransferase
(MGMT) promoter methylation for this important
subpopulation. For clarification, a prospective study
was conducted.
Methods Adult patients with a non-resectable
glioblastoma were included. A molecular stereotactic
biopsy technique was used for tumour characterisation
combining histopathological diagnosis with small
sample size adjusted methylation-specific PCR (MSP)
and sodium bisulfite sequencing. Treatment included XRT
(60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m2)/
TMZ (150e200 mg/m2 per day for 5 days of every
28-day cycle). The primary end point was
progression-free survival (PFS). Secondary endpoints
were overall survival (OS) and treatment response (TR).
Patients were categorised in the Radiation Therapy
Oncology Group (RTOG)-recursive partitioning analysis
(RPA) Classes III (N¼4), IV (N¼12), V (N¼28) and VI
(N¼12).
Results and discussion The success rates of MSP and
sequence analyses were 100%. The MGMT promoter
was methylated in 30/56 tumours, which was
associated with an increased PFS (median 56 versus
20 weeks; hazard ratio 0.15; range 0.07 to 0.33;
p<0.0001), higher frequency of TR (93.3% vs 46.2%;
p¼0.0008) and increased OS (median 104 vs 28 weeks;
hazard ratio 0.18; range 0.08 to 0.38; p<0.0001). The
transient perioperative morbidity was 1.8%.
Conclusion MGMT promoter methylation has
a predominant favourable influence even for the
important subpopulation with non-resectable
glioblastoma. The molecular stereotactic biopsy
technique is safe and effective for predictive evaluation
and helps to avoid both over- and undertreatment.
INTRODUCTION
The incidence of malignant gliomas has increased
over the last two decades, especially in the older
subpopulation, and currently lies in the range
of five cases per 100 000.1 Glioblastoma account
for approximately 60e70% of these tumours.
Recently, important progress has been achieved in
the treatment of this most malignant tumour. First,
radiotherapy plus concomitant and adjuvant
temozolomide (XRT/TMZ/TMZ) has resulted in
significant prolongation of both time to progression
and survival as compared with XRTalone; this was
demonstrated by the results of the prospective
randomised trial performed by the European
Organisation for Research and Treatment of Cancer
(EORTC) and the National Cancer Institute of
Canada (NCIC) Clinical Trials Group.2 3 Second,
epigenetic silencing of the promoter of the gene
that encodes O6-methylguanine-DNA methyl-
transferase (MGMT) in tumour specimens has been
identified as a favourable predictive factor of benefit
from XRT/TMZ/TMZ; this was shown in
a companion retrospective study.4
The impact of these findings on clinical practice,
however, is still under debate: subgroup analysis
suggests that relative young and/or fit patients
harbouring a tumour with a methylated MGMT
promoter and undergoing resection rather than
biopsy benefit most from XRT/TMZ/TMZ.2 It
remains unclear as to which extent unfavourable
prognostic factors such as increased age and/or a deep
seated tumour location might outweigh potential
benefit resulting from MGMT methylation.5 The
important subgroup of patients with non-resectable
glioblastoma is particularly concerned: patients
having undergone biopsy only experienced the worst
outcome in the EORTC/NCIC trial, which was
irrespective of treatment2dhowever, no stratifica-
tion by the MGMT methylation status was done,
because this biomarker could not be analysed from
small biopsy specimens.4 In this situation, oncolo-
gists are confronted with unawareness and uncer-
tainty concerning appropriate treatment strategies
for those patients not suitable for open tumour
resection. The current prospective study was
conducted to elucidate for the first time the prognosis
of patients with non-resectable glioblastoma under-
going XRT/TMZ/TMZ after adjustment for the
effects of MGMT promoter methylation and other
relevant prognostic factors. Characterisation of the
tumour was performed using the molecular stereo-
tactic biopsy techniquewhich combines state-of-the-
art histopathological evaluation with a small sample
size adjusted molecular genetic analysis.6e8 The
current study should not be regarded as an appendix
to the EORTC/NCIC trial. Both studies differ in
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METHODS
Patients
Adult patients (aged 18e85 years) were eligible if they had (1)
a supratentorial glioblastoma not suitable for gross total tumour
resection (because of an eloquent tumour location and/or
significant comorbidity) with histology being proven by
stereotactic biopsy, (2) no severe mass effect of the tumour
demanding debulking surgery because of brainstem compression
and/or midline shift, (3) no prior history of surgery, XRTand/or
chemotherapy, (4) a Karnofsky performance score (KPS) $609
and (5) adequate haematologic, renal and hepatic function (as
being defined before).3 All enrolled patients gave informed
consent. The study protocol was approved by the institutional
review board (AZ 216/14) of the Ludwig Maximilians University
Munich, Germany.
Molecular stereotactic biopsy technique
The still new technique of molecular stereotactic biopsy has
been described previously.6e8 In brief, coregistration of compu-
terised tomography (CT) and magnetic resonance imaging
(MRI; including T1- and T2-weighted sequences) served for
three-dimensional (3D) visualisation (i-plan stereotaxy,
BrainLAB, Feldkirchen, Germany) of the tumour and the simu-
lation of the best trajectory. Serial biopsies were taken along
a trajectory representative of the solid tumour. Using micro-
forceps, the maximum amount of tissue per biopsy specimen
was 1 mm3. The number of specimens taken in 1 mm steps
along the chosen trajectory was in the range of 10e18 samples
per tumour. The tissue-sampling procedure was guided by
intraoperative smear preparations, which were routinely
performed by the attending neuropathologist: only tumour
probes next (ie, 1 mm distance) to smear preparations exclu-
sively showing solid vital tumour tissue were used for molec-
ular genetic analysis; a corresponding sample (level +1 mm)
was taken for paraffin embedding and histopathological
examination using standard protocols.8 Samples chosen for
molecular genetic analysis were snap-frozen immediately after
withdrawal. The described biopsy technique was chosen to
minimise the risk of tissue contamination (eg, by non-
neoplastic or necrotic tissue) and, more importantly, to recog-
nise contamination, if it occurs. For determination of the
MGMT promoter methylation status, at least two tissue
samples were collected from different sites throughout each
tumour to test for both the intratumoural distribution of the
biomarker and the reproducibility of the molecular genetic
analysis. The histological diagnosis of all tissue specimens was
made according to the 2007 World Health Organization (WHO)
classification of tumours of the central nervous system.10 A
CT-scan was done 1 day after biopsy in all patients, and any
sequels attributed to the biopsy procedure were classified as
morbidity.11
Methylation-specific PCR (and sequencing analysis)
Isolation of nucleic acids, bisulfite modification of DNA, meth-
ylation-specific PCR (MSP) and sequencing analyses were done
as published previously in detail.8 12 In brief, DNA isolation from
tumour specimens was performed using the QIAamp DNA
Micro Kit (Qiagen, Hilden, Germany), and DNA recovery from
each stereotactic biopsy sample amounted to around 30e60 ng/
ml. This step was followed by purification and bisulfite modifi-
cation of DNA according to Mollemann et al.12 MSP and
sequencing analyses were performed using the specific primer
pairs as described previously.13e15 ‘Unmethylated’ and ‘methyl-
ated’ tumours were defined according to Grasbon-Frodl et al.8
Sequencing of bisulfite-modified DNA indicated a methylated
promoter when more than half of the CpG sites (13 of 25 CpG
sites) were found to be methylated; partial methylation was
defined as the cytosine and thymine peaks being equally sized or
the cytosine peak being twice as high as the corresponding
thymine peak.
Study design
Patients were enrolled in the period fromMarch 2006 to August
2008. Patients were categorised according to the Radiation
Therapy Oncology Group (RTOG)-recursive partitioning
analysis (RPA) classes.16 The KPS was used for clinical evalu-
ation.9 Rating on the KPS was done independently by two
investigators (NT and FWK). In case of discordantly rated
performance scores, a third investigator (JCT) was introduced,
and the most matching score was used thereafter. Histopath-
ological diagnosis and determination of the MGMT methyla-
tion status were obtained within 5e7 working days. Within
3 weeks after stereotactic biopsy, patients were assigned to
receive XRT/TMZ/TMZ: treatment included XRT (60 grey in
30 fractions)/TMZ [daily dose of 75 mg/m2]/TMZ
(150e200 mg/m2 per day for 5 days of every 28-day cycle). In
case of long-term compliance, however, TMZ was continued
(at the same dose) until tumour progression occurred. At
baseline evaluation, 4e6 weeks after XRT/TMZ and every
three cycles during TMZ maintenance therapy, clinical and
neuroradiological examinations were performed (until last
follow-up). MRI interpretation was independently done
according to the Macdonald criteria17 by an experienced
neuroradiologist (JL), who was blinded for the MGMT status
and the follow-up data of the patient. Treatment response was
evaluated after the completion of three TMZ cycles or earlier in
case of clinical deterioration. Tumour progression had to be
confirmed by further clinical and neuroradiological follow-up
to exclude any bias by pseudoprogression.18 Additional meta-
bolic imaging19 and/or stereotactic rebiopsy were considered
necessary, when further (modified) invasive treatment strate-
gies were under consideration. Haematology was performed
weekly. Adverse events were defined according to the National
Cancer Institute (NCI) Common Toxicity Criteria, version 3.0.
The minimum follow-up after inclusion of the last patient had
to be 6 months.
Statistical analysis
The hazard ratio for tumour progression was in the range of 0.48
in favour of the MGMT promoter methylated group in the
study of Hegi et al.4 In the absence of cytoreductive surgery, we
expected an even more pronounced outcome difference; this
assumption was indirectly supported by the study of Chinot
et al,20 who have found highly divergent outcome scores as
a function of MGMT expression after neoadjuvant TMZ of
non-resectable glioblastoma (median progression-free survival
(PFS): 5.5 vs 1.9 months). In the current series, a hazard ratio of
0.4 or even less in favour of the MGMT promoter methylated
group was expected. Assuming exponential survival, we esti-
mated that a sample size in the range of 27 patients or more in
each group would be sufficient to have a power of 80% to
demonstrate a significant difference in PFS in favour of glio-
blastoma with a methylated MGMT promoter.
The reference point of this study was the date of the diag-
nosis. The primary endpoint was PFS; secondary endpoints
were treatment response (TR) and overall survival (OS). PFS
and OS were analysed by the KaplaneMeier method21 and
compared with the two-sided logrank test. Logistic regression
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models were used to analyse the association between TR and
other variables. The Cox model was fitted to assess the prog-
nostic value of the MGMT methylation status and other
potential prognostic factors.22 First, the importance of each
variable was tested univariately. Second, all variables were
fitted together. The ‘BEST’ model contained only variables
associated with PFS or OS after adjustment for the effects of
the other variables. The distribution of patient- and tumour-
related variables between MGMT promoter methylated and
unmethylated subgroups was analysed by the c2 statistics (for
dichotomised variables) and the Wilcoxon test (for continu-
ously scaled variables). A p value of #0.05 was considered
significant. All calculations were performed using the SAS
software package (version 9.1).
RESULTS
Patient characteristics
Out of an overall number of 136 patients newly diagnosed as
having a glioblastoma in our department between March 2006
and August 2008, a total of 56 consecutive patients (33 men, 23
women) fulfilled inclusion criteria and were enrolled in this
study. Patients were categorised into RTOG-RPA class III (four
patients, 7.1%), class IV (12 patients, 21.4%), class V (28
patients, 50.0%) and class VI (12 patients, 21.4%). The median
of the age distribution was 62.5 years (range 23e85 years); 22
(39%) patients were 65 years of age or older. The median KPS
was 70; 24 patients (42.9%) experienced a KPS of 70, and 13
a KPS of 60 (23.2%). Forty-eight patients (85.7%) exhibited
multifocal (six patients) or eloquent (42 patients) tumour loca-
tions including involvement of the primary motor/sensory
cortex (10 patients), speech area (eight patients), visual cortex
(three patients), basal ganglia (16 patients) and the corpus
callosum (five patients). Stereotactic biopsy procedures were
associated with a transient morbidity of 1.8% (one patient with
transient aphasia). MSP and sequencing analyses always
exhibited concordant and reproducible results throughout each
tumour (mean number of samples per tumour: 3; range 2e5).
The overall frequency of MGMT methylated tumours was
53.6% (30/56) including one patient with a partially methylated
promoter. Methylated and unmethylated subpopulations did
not differ with respect to patients’ characteristics, even though
patients with a methylated MGMT promoter were somewhat
younger (table 1).
One patient was lost to follow-up 24 weeks after biopsy
without experiencing tumour progression at this time. Two
patients had to be discontinued from concomitant TMZ after 3
and 4 weeks, respectively, because of grade 3 haematological
toxicity and lung embolism. Adjuvant TMZ was not initiated in
three patients because of low clinical performance (KPS<60)
after XRT/TMZ, which was associated with a decline in the
mental status (disorientation and confusion). TMZmaintenance
therapy caused grade 1/2 toxicity in 12 patients. As a conse-
quence of grade 3 toxicity, adjuvant TMZ had to be interrupted
for 4 weeks in two patients and to be discontinued after two
cycles in one patient (table 2).
Adverse events were more often seen in older patients (median
age of patients with/without adverse events: 70 versus
57.5 years; p<0.03). The application of more than six TMZ
cycles (15 patients with a median number of nine TMZ cycles)
was not associated with increased toxicity. However, late grade 2
haematotoxicity was seen in two patients after the 11th and
14th cycle of TMZ, respectively. MRI-based suspicion of tumour
progression was additionally verified by metabolic imaging
[O-(2-[18F]fluoroethyl)-L-tyrosine (FET) positron emission
tomography (PET)] in 20 patients and/or rebiopsy in 13
patients; the latter always revealed an unchanged MGMT
promoter methylation status.
Table 1 Characteristics and clinical outcome of patients with






Age (years) Median 64.5 58.5 NS
<50 7 (26.9%) 10 (33.3%)
50e60 3 (11.6%) 6 (20.0%)
>60 16 (61.6%) 14 (46.7%)
Karnofsky performance
score





III 1 (3.8%) 3 (10.0%)
IV 6 (23.1%) 6 (20.0%)
V 12 (46.2%) 16 (53.3%)
VI 7 (26.9%) 5 (16.7%)
Sex Male 15 (57.7%) 18 (60.0%) NS
Female 11 (42.3%) 12 (40.0%)
Tumour volume (ml) Mean (SD) 43.7 (624.9) 38.8 (631.2)
Tumour side Right 10 (38.5%) 14 (46.7%) NS
Left 16 (61.5%) 16 (53.3%)
Tumour location Lobar 3 (11.5%) 5 (16.7%) NS
Eloquent 21 (80.8%) 21 (70.0%)





3 (11.6%) 17 (56.7%)
Stable
disease
9 (34.6%) 11 (36.6%)


























0.18 (0.08 to 0.38)
NS, not significant.
Table 2 Toxicity symptoms*
No of patients (%) (N[56)
National Institute of Cancer Common
Toxicity Criteria Grade
1e2 3e4
Myelosuppression 4 (7) 3 (5.4)
Thrombosis MV 4 (7)
Nausea 9 (16) MV
Infection 5 (9) MV
Mental statusy 7 (13) 7 (13)
Otherz 4 (7) 1 (2)
*One patient can suffer from multiple symptoms.
yIncluding cognitive impairment, disorientation, confusion, depression and psychosis.
zIncluding hypocortisolism, apoplex, cardial dysrhythmias and pruritus.
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Clinical outcome
The median follow-up time was 48 weeks (range 24e144) for
the survivors. Forty-one out of 56 patients exhibited tumour
progression, and 34 patients had died. Death was tumour-related
in all patients. KaplaneMeier estimates for PFS and OS of the
whole study population are presented in figure 1. Both primary
and secondary end points were in favour of MGMT promoter
methylated tumours (table 1): MGMT promoter methylated
tumours exhibited superior median PFS (56 vs 20 weeks) and
superior median OS (104 vs 28 weeks); PFS after 6 (12) months
was 83.3% (54.4%) for MGMT promoter methylated tumours
and 34.6% (0%) for those with an unmethylated MGMT
promoter (p<0.0001) (figure 2). The corresponding 6 (12)
months survival rates were 90.0% (64.8%) and 57.7% (13.2%),
respectively (p<0.0001) (figure 2). Among patients with MGMT
promoter methylation, the unadjusted hazard ratio for disease
progression and death was 0.15 (95% CI 0.07 to 0.33) and 0.18
(95% CI 0.08 to 0.38), respectively.
Treatment responders showing partial response or stable
disease (3 months after treatment) were more often seen in case
of a methylated MGMT promoter (28/30 MGMT methylated
tumours vs 12/26 unmethylated tumours; p¼0.0008). Treatment
responders were younger and experienced a longer OS than
non-responders (median: 72 vs 18 weeks; p<0.0001) (see table 3).
The survival advantage, however, was less pronounced for
those with an unmethylated MGMT promoter (median:
44 weeks vs 104 weeks, p<0.001). At the time of tumour
progression, treatment concepts included second-line chemo-
therapy (n¼16), reirradiation (n¼4), tumour debulking due to
significant space occupying effects (n¼2), stereotactic brachy-
therapy (n¼3), a combination of these treatment modalities
(n¼8) and palliative care (n¼23). The median survival after
progression was longer for methylated tumours (3.7 months
versus 1.9 months); the difference, however, was not significant.
Prognostic and predictive factors
Univariately, MGMT promoter methylation, younger age,
higher KPS scores and RTOG-RPA classes III+IV were positively
correlated with both increased PFS and OS. In the ‘BEST’
prognostic Cox models, only MGMT promoter methylation
status (OS: p<0.0001; PFS: p<0.0001), younger age (PFS:
p¼0.02) and higher KPS scores (OS: p¼0.02) remained statisti-
cally significant (table 4).
The adjusted hazard ratio of 0.2 (95% CI 0.09 to 0.43) of
MGMT promoter methylation for PFS was consistent with the
unadjusted hazard ratio of 0.15 (95% CI 0.07 to 0.33). Logistic
regression analysis identified MGMT promoter methylation as
the only predictor for TR (partial response or stable disease;
p¼0.0008); the prognostic influence of age (which was detected
in one-variable models) was lost.
DISCUSSION
Currently, patients with non-resectable glioblastoma undergoing
XRT/TMZ/TMZ are left with uncertainties concerning their
prognosis. Moreover, they are unlikely to be entered into rand-
omised clinical trials, addressing molecular biomarkers such as
MGMT methylation for patient stratification. Difficulties in
performing molecular genetic analyses from small biopsy speci-
mens have so far added to these barriers in knowledge and
scientific evaluation.4 Here, we show in a prospective consecu-
tive series of 56 non-resectable glioblastoma patients that by
means of the still new technique of molecular stereotactic
biopsy, even this somewhat neglected patient population can be
addressed: overall survival for patients of this study cohort was
similarly poor as compared with those undergoing biopsy only
in the EORTC/NCIC trial.2 Outcome measurements, however,
became highly divergent after stratification forMGMT promoter
methylation. Whereas patients harbouring a glioblastoma with
an unmethylated MGMT promoter experienced both extremely
short PFS and OS, those with a methylated promoter exhibited
surprisingly long PFS and OS. The time to progression was
similar to that reported by Hegi et al4 after cytoreductive surgery
Figure 1 KaplaneMeier estimates of progression-free survival and
overall survival among patients with glioblastoma who were diagnosed
by stereotactic biopsy and prospectively treated with radiotherapy plus
concomitant and adjuvant temozolomide.
Figure 2 KaplaneMeier estimates of
progression-free survival (A) and overall
survival (B) among patients with
glioblastoma stratified for the MGMT
promoter methylation status who were
diagnosed by stereotactic biopsy and
prospectively treated with radiotherapy
plus concomitant and adjuvant
temozolomide. meth, methylated;
unmeth, unmethylated.
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plus XRT/TMZ/TMZ. Survival after tumour progression,
however, was shorter in the current series. One may speculate
that the relatively large tumour volumes, which were not
reduced by open surgery, have led to a relatively delayed diag-
nosis of tumour progression (using the Macdonald criteria).17 It
should be further noted that a considerable number of patients
received more than six cycles of TMZ in our series, which
indicate an important difference to the EORTC/NCIC trial;
accordingly, any comparative analysis should be avoided at this
moment.
Early tumour progression was associated with poor outcome
in all patients of this series. Apparently, pseudoprogression does
not seem to be a frequent event in non-resectable glioblastoma
patients undergoing XRT/TMZ. Partial response or tumour
control (3 months after XRT/TMZ) was a strong predictor for
a more favourable outcome and not unequivocally related to the
MGMT promoter status: 93.3% of the MGMT methylated and,
noteworthy, 46.2% of the unmethylated tumours exhibited
partial response/stable disease after XRT/TMZ/TMZ.
Survival, however, was significantly longer in case of a methyl-
ated MGMT promoter. Thus, for treatment responders with an
unmethylated MGMT promoter, the benefit of XRT/
TMZ/TMZ as compared with XRT alone continues to be
unclear. Future studies are required that further elucidate the
molecular network of epigenetic silencing of the MGMT
promoter and MGMT gene expression in correlation with clin-
ical course and prognosis.23
Molecular stereotactic biopsy turned out to be a safe (tran-
sient morbidity of as low as 1.8% in this series) and precise
diagnostic procedure. The highly controlled sampling technique
ensured the use of only vital tumour tissues for subsequent
molecular analyses, and excluded bias of the results by
non-neoplastic tissue contaminations. Handling of nucleic acids
as well as routine setup for MSP and sequencing analyses was
successfully adapted to the small tissue samples containing
limited amounts of nucleic acids.8 Due to these efforts, there
were no drop-outs due to difficulties in determining the MGMT
promoter status: the success rates of MSP and sequencing were
100%, and both methods exhibited 100% concordant findings
throughout each tumour investigated. The latter indicates
a homogenous intratumoural distribution of the biomarker. The
overall frequency of tumours harbouring a methylated MGMT
promoter was 53.6%, which was slightly higher than in the
study by Hegi et al (MGMT promoter methylated tumours:
45%)4; the difference between these studies was not statistically
significant and might have occurred by chance. However, the
exact assignment of each biopsy specimen within the stereo-
tactically defined tumour space, the determination of its relation
to tumour necrosis or non-neoplastic tissue by alternating
histopathological and molecular evaluation within 1 mm steps,
the simultaneous application of two molecular genetic methods
at different sites of each tumour and the exclusive use of cryo-
preserved specimens indicate important differences from the
study by Hegi et al.4
We further demonstrate that the MGMT status after XRT/
TMZ/TMZ remained unchanged, which was seen in 13
patients undergoing stereotactic rebiopsy because of tumour
progression. Both the detected intratumoural homogeneous
distribution of the MGMT promoter methylation status and its
unchanged pattern before and after XRT/TMZ/TMZ suggest
that MGMT promoter methylation may be a rather early event
in tumour genesis.
In summary, the current series describes for the first time the
powerful treatment effects of XRT/TMZ/TMZ for patients
with non-resectable glioblastoma in case of a methylated
MGMT promoter. It underscores that non-resectable tumours
should not be associated per se with a worse prognosis as
compared with those undergoing open tumour resection. The
demonstrated high diagnostic sensitivity and specificity of MSP










Median age (years) 68.5 59.0 0.04
O6-methylguanine-DNA
methyltransferase methylated
2 (12.5%) 28 (70.0%) 0.0008
O6-methylguanine-DNA
methyltransferase unmethylated
14 (87.5%) 12 (30.0%)
Outcome
Overall survival <0.0001
Median (weeks) 18 72
Rate at 6 months 37.5% 90.0%
Rate at 12 months 0% 58.6%
N, number of patients.
Table 4 Prognostic factors (univariate and multivariate models)
p Value (hazard ratio/95% CI)




<0.0001 (0.15/0.07 to 0.33) <0.0001 (0.18/0.08 to 0.38)
Age 0.01 (1.03/1.01 to 1.06) 0.009 (1.04/1.01 to 1.08)
Karnofsky performance score 0.01 (0.95/0.92 to 0.99) 0.003 (0.94/0.90 to 0.98)
Radiation Therapy Oncology Group 0.04 (1.57/1.02 to 2.43) 0.01 (1.85/1.13 to 3.04)
Location of tumour NS NS
Volume of tumour NS NS




<0.0001 (0.16/0.07 to 0.35) <0.0001 (0.20/0.09 to 0.44)
Age 0.02 (1.03/1.0 to 1.06) NS
Karnofsky performance score NS 0.02 (0.95/0.91 to 0.99)
NS, not significant.
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and sequence analysis in combination with stereotactic biopsy
technique might help to encourage the further development and
implementation of molecular genetic analysis into biopsy
procedures of daily clinical practice.
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